title: Selegiline for neuroleptic-induced parkinsonism.
authors.affiliation: Department of Clinical Psychobiology-New York State Psychiatric Institute/Columbia University Department of Psychiatry.
authors.forename: G R
authors.initials: GR
authors.lastname: Gewirtz
authors.forename: Z
authors.initials: Z
authors.lastname: Sharif
authors.forename: J L
authors.initials: JL
authors.lastname: Cadet
authors.forename: P
authors.initials: P
authors.lastname: Sarti
authors.forename: J M
authors.initials: JM
authors.lastname: Gorman
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D012642:Selegiline; D006220:Haloperidol